Aether Industries Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Aether Industries Ltd filed with BSE on 07 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Aether Industries reported Q1 FY27 consolidated revenue growth of 27% year-over-year to INR3,266 million, with EBITDA up 31% to INR1,028 million and PAT up 33% to INR627 million. Management described a new collaboration with Dow Chemical to develop silicone manufacturing technology and highlighted advanced electronic materials for 5G and AI semiconductor applications as a new growth vector. Management also discussed capacity utilization across sites, the CEM and CRAMS business mix, and progress on the Magnum Site 5 expansion in Panoli.
Numbers mentioned
Revenue: INR3,266 million (Q1 FY27)
p. 6
“The consolidated revenue for Q1 of FY27 has increased by 27% year-over-year, and it has reached INR3,266 million in this quarter as against INR2,566 million in Q1 of FY26.”
Faiz Nagariya, page 6 of the filed PDF · View the filing
EBITDA: INR1,028 million (Q1 FY27)
p. 7
“The EBITDA has reached INR1,028 million in Q1 FY27, as against INR785 million in Q1 of FY26, which is an increase of 31% year-over-year.”
Faiz Nagariya, page 7 of the filed PDF · View the filing
EBITDA margin: 31% (Q1 FY27)
p. 7
“EBITDA margins stood at 31% in this Q1 of FY27 as against 30% in Q1 FY26.”
Faiz Nagariya, page 7 of the filed PDF · View the filing
PAT: INR627 million (Q1 FY27)
p. 7
“The PAT amounted to INR627 million in Q1 of FY27, as against INR470 million in Q1 FY26, which is an increase of 33% year-over-year.”
Faiz Nagariya, page 7 of the filed PDF · View the filing
PAT margin: 19% (Q1 FY27)
p. 7
“The PAT margin stood at 19% in Q1 of '27, as against 18% of Q1 of FY26.”
Faiz Nagariya, page 7 of the filed PDF · View the filing
Capex: INR943 million (Q1 FY27)
p. 7
“The total capex for Q1 of FY27 was INR943 million.”
Faiz Nagariya, page 7 of the filed PDF · View the filing
Capacity utilization Site 2: 74% (Q1 FY27)
p. 7
“The capacity utilization at all plants stands as under Site 2, 74% Site 3, 69% and Site 4, 59%.”
Faiz Nagariya, page 7 of the filed PDF · View the filing
CEM EBITDA margin range: 28% to 30%
p. 4
“CEM runs at EBITDA margins north of 28% to 30%, so every point of mix that shifts towards this model makes our earnings both larger and more resilient.”
Rohan Desai, page 4 of the filed PDF · View the filing
New marquee clients onboarded: 10 (Q1 FY27)
p. 4
“In Q1 FY 2027, we have onboarded 10 new marquee clients and cleared more than nine customer and certification audits.”
Rohan Desai, page 4 of the filed PDF · View the filing
LSM volume decline: 22.5% (Q1 FY27)
p. 17
“So baiscally, the LSM business model, basically, if you see there’s a decline of 22.5% in terms of volume.”
Kushal Doshi, page 17 of the filed PDF · View the filing
LSM pricing improvement: 22.5%
p. 17
“We’ve seen pricing improve by 22.5% also on the back of the products which we have.”
Kushal Doshi, page 17 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Magnum Phase 1 asset turn — 1.5 to 1.75
stated as an aspiration by Aman Desai
p. 5
“Phase 1 has become online and once fully operational, we expect asset turn of 1.5 to 1.75.”
Aman Desai, page 5 of the filed PDF · View the filing
Magnum total investment — INR2,200 crores to INR2,300 crores
stated firmly by Aman Desai
p. 5
“The total investment is in the order of INR2,200 crores to INR2,300 crores.”
Aman Desai, page 5 of the filed PDF · View the filing
Magnum Phase 2 commissioning — FY 2030
stated firmly by Aman Desai
p. 5
“Phase 2, FY 2030.”
Aman Desai, page 5 of the filed PDF · View the filing
CEM and CRAMS revenue contribution — 70+ percentage of revenue · next couple of years
stated as an aspiration by Rohan Desai
p. 4
“we have a clear line of sight to these two models contributing 70+ of our -- percentage of our revenue in the next couple of years”
Rohan Desai, page 4 of the filed PDF · View the filing
R&D facility commissioning — FY 2028
stated firmly by Aman Desai
p. 6
“A much larger R&D facility, as you know, with around 15 new labs and close to 160 cumulative fume hoods, is on track for commissioning in FY 2028.”
Aman Desai, page 6 of the filed PDF · View the filing
FY27 capex — INR3,000 million to INR3,500 million · FY27
stated firmly by Faiz Nagariya
p. 7
“The capex expected for FY27 is expected to be between INR3,000 million to INR3,500 million.”
Faiz Nagariya, page 7 of the filed PDF · View the filing
LSM products revenue contribution — Q2 FY27
stated firmly by Rohan Desai
p. 8
“And we expect them to start contributing to our revenue in Quarter 2 of financial year 2027.”
Rohan Desai, page 8 of the filed PDF · View the filing
Semiconductor materials capacity — 3x by 2030 · by 2030
stated as an aspiration by Rohan Desai
p. 11
“We are starting with capacities of 400 tons at this point of time, which is supposedly going to grow 3x by 2030.”
Rohan Desai, page 11 of the filed PDF · View the filing
Semiconductor Magnum site capacity online — 45 tons per month · end of September
stated firmly by Rohan Desai
p. 15
“whereby we’ll come out with 45 tons per month capabilities split it into 3 streams of 15 tons each. And that is going to be online in end of September.”
Rohan Desai, page 15 of the filed PDF · View the filing
LSM contribution to top line — 35% · few years
stated as an aspiration by Rohan Desai
p. 14
“the LSM product line business segment is important to us, even though it will contribute only 35% of our total top line in the few years to come.”
Rohan Desai, page 14 of the filed PDF · View the filing
Dow silicones commercialization timeline
stated conditionally by Aman Desai
p. 9
“As you can understand, we can’t put a revenue date on this right now.”
Aman Desai, page 9 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said they cannot disclose order book details for competitive reasons but confirmed the chemistry draws on core CRAMS/CEM competencies.
Answered by Rohan Desai
Asked by Nilesh Ghuge: Are there any orders in hand for the semiconductor segment and which chemistries are involved?
p. 7
“So Nilesh, for the competitive reasons, we don't break out our order book or the product count for the program at this stage.”
Rohan Desai, page 7 of the filed PDF · View the filing
Management described it as a platform technology program in stages -- R&D, pilot validation, then potential commercialization framework -- and said no revenue date could be given yet.
Answered by Aman Desai
Asked by Chaitanya Kamdar: What is the scope and timeline of the Dow collaboration and what should investors track?
p. 9
“Think of it in stages, R&D and process development first, pilot scale validation, and then in the -- this agreement also establishes a framework for the potential manufacturing and commercialization of this technology.”
Aman Desai, page 9 of the filed PDF · View the filing
Management declined to give a specific timeline, describing it as a firm, dedicated multiyear program.
Answered by Aman Desai
Asked by Keshav Bharadia: What is the timeline for the Dow research program to reach industrial scale and how large could the opportunity be?
p. 10
“So let us not comment on a specific time line right now, but it is a firm program.”
Aman Desai, page 10 of the filed PDF · View the filing
Management said their focus is on advanced electronic materials and specialty monomers rather than fab-level consumables like gases and photoresists.
Answered by Rohan Desai
Asked by Soham Jain: How does Aether's semiconductor materials offering differ from Sumitomo's high purity process chemicals push in India?
p. 13
“Our entry point is advanced electronic materials, specifically the low dielectric materials inside high-speed circuit boards for 5G and AI hardware applications.”
Rohan Desai, page 13 of the filed PDF · View the filing
Management said the decline reflected reallocation of production lines to CEM, not lost demand, and that LSM pricing improved.
Answered by Kushal Doshi
Asked by Divya Kasera: Did the 22% YoY LSM volume decline reflect lost orders, and what happened to margins on reallocated capacity?
p. 17
“But that’s primarily on the back of us dedicating some of the production lines to the CEM business model, which we’ve done in site 3.”
Kushal Doshi, page 17 of the filed PDF · View the filing
Management confirmed Baker Hughes is the largest driver, scaling from a smaller base a year earlier, alongside other customers.
Answered by Kushal Doshi
Asked by Divya Kasera: Is the Oil and Gas segment revenue driven mainly by Baker Hughes or is it broad-based?
p. 17
“Today, Site 4 is already producing close around INR70 odd crores with clear line of sight, which we have for demand for these products.”
Kushal Doshi, page 17 of the filed PDF · View the filing
Management named safety and execution capability as the two main risks, and said they remain cognizant of the limitations of their team.
Answered by Aman Desai
Asked by Pankaj K.: What risks could derail execution given simultaneous expansion, segment mix shift, and the new Dow partnership?
p. 18
“The problem -- the potential problems and the challenges I have always maintained in the chemical industry is safety.”
Aman Desai, page 18 of the filed PDF · View the filing
Risks flagged
Safety in chemical processes
p. 18
“The problem -- the potential problems and the challenges I have always maintained in the chemical industry is safety.”
Aman Desai, page 18 of the filed PDF · View the filing
Execution capability to run manufacturing plants safely and sustainably
p. 18
“And the second one, especially now for companies like us in India is our ability to execute, right?”
Aman Desai, page 18 of the filed PDF · View the filing
Uncertainty around ISM 2.0 structure for potential benefit
p. 11
“I’ll not promise anything at the moment because the structure is still not clear.”
Rohan Desai, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.